Colorectal Carcinoma Clinical Trial
Official title:
Cancer Communication Within Social Networks
Verified date | June 2020 |
Source | Fred Hutchinson Cancer Research Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial examines cancer communication within Hispanic social networks. Hispanics have the lowest colorectal cancer screening rate of any major ethnic group and health interventions are crucially needed among Hispanics. Patient decision aids are health communication interventions designed to provide patients with targeted health information and have shown to improve colorectal cancer screening rates among Hispanics. The goal of this study is to investigate, in a sample of Hispanics, how a colorectal cancer decision aid aimed at increasing individuals' colorectal cancer screening behavior has effects on their alters' intention to get screened for colorectal cancer.
Status | Completed |
Enrollment | 57 |
Est. completion date | March 9, 2015 |
Est. primary completion date | February 10, 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Self-identify as "Hispanic" or "Latino" - Have no family history of CRC - Have no personal history of pre-cancerous (adenomatous) colonic polyps - Have not had either an annual fecal occult blood test (FOBT) within the past year or colonoscopy within the last 10 years (defined as up-to-date with CRC screening by current United States [U.S.] Preventive Services Task Force recommendations) - Have at least two family members, friends, or co-workers who are ages 50-75 - Alters will be eligible if they are ages 50-75 |
Country | Name | City | State |
---|---|---|---|
United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patients' communication with their families, friends, and co-workers about colorectal cancer (CRC) screening | Will be assessed using a single dichotomized question with two response options ('yes' or 'no'). CRC communication constitutes in-person conversation, email, phone, or post on social media (e.g., blog, Twitter, Facebook). Will also assess the characteristics of the alters by asking the patients two questions on social-tie dimensions: 1) contact frequency (never, rarely, sometimes, often, or very often) and 2) personal relationship (acquaintance , close friend , co-worker, relatives, or spouse). | Up to 6 months | |
Primary | Alters' intent to become screened for CRC in the next six months | Intent will be assessed using a single categorical item with three response options (definitely planning to be screened, considering being screened, not considering being screened). | Up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06233253 -
Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy
|
N/A | |
Recruiting |
NCT05799820 -
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
|
Phase 2 | |
Recruiting |
NCT04666727 -
Role of Diet on the Microbiome of the Digestive System
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT02376452 -
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
Phase 2 | |
Completed |
NCT02254486 -
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
|
Phase 3 | |
Completed |
NCT01486251 -
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
|
N/A | |
Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00485316 -
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
|
Phase 3 | |
Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Not yet recruiting |
NCT03969784 -
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
|
N/A | |
Completed |
NCT04607291 -
Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
|
Phase 1 | |
Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT05291988 -
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 |